NYSEHealth CareHealth Care ServicesS&P SmallCap 600
$42.22
+0.07 (+0.17%)
Close of Nov 06, 2026 · end-of-day data
CON 8-K filings in 2025
Every material Form 8-K Concentra Group Holdings Parent filed with the SEC in 2025, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
On November 4, 2025, Concentra's Human Capital and Compensation Committee awarded restricted common stock to six named executive officers under its 2024 Equity Incentive Plan. The awards vest equally over four years, and the largest grant, 225,000 shares, went to CEO W. Keith Newton.
Grant date: November 4, 2025, under the 2024 Equity Incentive Plan
W. Keith Newton received 225,000 restricted shares; Matthew T. DiCanio received 180,000
Four other named executive officers each received 60,000 restricted shares
Shares vest equally on each of the first four anniversaries of the grant date
Concentra Group Holdings reported third-quarter 2025 revenue of $572.8 million, up 17.0% from a year earlier, and net income of $49.8 million, up 8.9%. The company raised its full-year 2025 guidance and authorized a $100 million share repurchase program. For the nine months, net income fell 8.3% to $136.7 million, which the company attributed to higher interest expense from its IPO recapitalization.
Q3 2025 revenue of $572.8 million, up 17.0% from $489.6 million; net income of $49.8 million, up 8.9%
Q3 earnings per share of $0.38, compared with $0.37 in Q3 2024
Raised 2025 guidance: revenue of $2.145 billion to $2.160 billion and Adjusted EBITDA of $425 million to $430 million
Board authorized a $100 million share repurchase program expiring December 31, 2027, and declared a $0.0625 per share dividend payable December 9, 2025
Concentra Group Holdings Parent reported second-quarter 2025 revenue of $550.8 million, up 15.2%, and raised its full-year 2025 revenue and Adjusted EBITDA guidance. Net income fell 12.9% to $46.2 million, and earnings per share fell to $0.35 from $0.50, which the company attributed to higher interest expense from its IPO recapitalization.
Q2 2025 revenue was $550.8 million, up 15.2% from $477.9 million; Adjusted EBITDA was $115.0 million, up 13.2% from $101.6 million.
Q2 2025 net income was $46.2 million versus $53.1 million a year earlier; EPS was $0.35 versus $0.50.
2025 revenue guidance was raised to $2.13 billion to $2.16 billion, and Adjusted EBITDA guidance is $420 million to $430 million.
The board declared a cash dividend of $0.0625 per share, payable August 28, 2025, to holders of record on August 21, 2025.
Concentra Group Holdings Parent, Inc. appointed Vipin Gopal and Brigid Bonner as directors on June 26, 2025, effective July 1, 2025, according to an 8-K filing. The filing says the company's board expands to seven members, and the two directors will be eligible for non-employee director compensation.
Appointments are effective July 1, 2025; the board is expanded to seven members.
Gopal's term expires at the 2026 Annual Meeting of Stockholders; Bonner's term expires at the 2027 Annual Meeting.
Both will receive non-employee director compensation as described in the proxy statement filed March 18, 2025.
The filing states neither director has a related party transaction requiring disclosure under Item 404(a) of Regulation S-K.
Concentra Health Services, a Concentra Group Holdings Parent subsidiary, closed its acquisition of Onsite Innovations on June 1, 2025, for a purchase price of $55 million, subject to customary adjustments. The deal was funded with cash on hand and revolving credit facility borrowing, and adds about 200 onsite health clinics in over 40 states. The filing does not include financial results for the acquired business, so its effect on earnings is not disclosed.
Purchase price: $55 million, subject to customary adjustments, paid with cash on hand and revolving credit facility borrowings
Acquisition closed June 1, 2025, under an equity purchase agreement dated April 18, 2025 with Pivot Occupational Health, LLC
Onsite Innovations operates about 200 onsite health clinics in over 40 states; the company says its onsite network expands to about 350 clinics
Concentra reported first-quarter 2025 revenue up 7.1% to $500.8 million and raised its full-year 2025 revenue and Adjusted EBITDA guidance. Net income fell 19.2% to $40.6 million, and earnings per share were $0.30 versus $0.47, which the company attributed to higher interest expense from its IPO recapitalization. The Board also declared a $0.0625 per share cash dividend.
Q1 2025 revenue was $500.8 million, up from $467.6 million; net income was $40.6 million, down from $50.3 million
Earnings per share were $0.30 versus $0.47 a year earlier; adjusted EPS was $0.32 versus $0.49
2025 guidance now calls for revenue of $2.1 billion to $2.15 billion and Adjusted EBITDA of $415 million to $430 million
Dividend of $0.0625 per share is payable May 29, 2025, to holders of record on May 20, 2025; the $55 million Pivot Onsite Innovations acquisition is expected to close in Q2 2025
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Concentra Group Holdings Parent filing is on SEC EDGAR ↗. 8-K briefs of other companies →